Search Result

Results for "

EPAC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (3) Akt (1) ERK (1) Fluorescent Dye (1) NF-κB (1) Phosphodiesterase (PDE) (2) PKA (9) PKG (1) Potassium Channel (2) Ras (22) Reference Standards (2) RSV (1) Small Interfering RNA (siRNA) (2) STAT (2) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (14) Infection (1) Inflammation/Immunology (1) Metabolic Disease (11) Neurological Disease (3)
Oligonucleotides:	Human Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16704

ESI-09 Maximum Cited Publications 9 Publications Verification	Virus Protease	Cancer
ESI-09 is a novel noncyclic nucleotide *EPAC* antagonist with IC₅₀ values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively.

HY-107543

8-pCPT-2′-O-Me-cAMP sodium 1 Publications Verification 8-CPT-2'-O-Me-cAMP sodium	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-117656

ESI-05 4 Publications Verification NSC 116966	Acyltransferase	Neurological Disease Metabolic Disease
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .

HY-108539

CE3F4 2 Publications Verification	Ras	Cardiovascular Disease
CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC₅₀s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC₅₀ of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent *Epac* activator .

HY-103322

6-Bnz-cAMP sodium salt	PKA Potassium Channel	Metabolic Disease Cancer
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K ⁺ channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K ⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .

HY-136172

ESI-08 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
ESI-08 is a potent and selective *EPAC* antagonist, which can completely inhibit both *EPAC1* and *EPAC2* (IC₅₀ of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced *EPAC* activation, but does not inhibit cAMP-mediated PKA activation .

HY-117958

HJC0197 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
HJC0197 is a potent *Epac1* (exchange protein directly activated by cAMP 1) and *Epac2* (IC₅₀=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP .

HY-126133

AM-001	Ras	Cardiovascular Disease Others
AM-001 is a non-competitive inhibitor of *Epac1* that blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells. AM-001 can be used in heart disease-related research .

HY-111446

EPAC 5376753	Ras	Cardiovascular Disease Metabolic Disease Cancer
EPAC 5376753, a 2-Thiobarbituric acid (HY-77962) derivative, is a selective and allosteric *Epac* inhibitor. EPAC 5376753 inhibits Epac1 with an IC₅₀ of 4 µM in Swiss 3T3 cells. EPAC 5376753 does not inhibit PKA and adenylyl cyclases .

HY-15702

HJC0350 2 Publications Verification	Ras	Cancer
HJC0350 is a potent and specific *EPAC2* antagonist with an IC₅₀ of 0.3 μM.

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates *Epac-Rap* signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating *Epac* from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .

HY-108539A

(R)-CE3F4 1 Publications Verification	Ras	Metabolic Disease
(R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC₅₀ of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC₅₀, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4 .

HY-129738

I942	Ras	Cardiovascular Disease
I942 is a first in class, selective non-cyclic nucleotide (NCN) EPAC1 agonist. I942 can attenuate proinflammatory cytokine signalling normally associated with cardiovascular diseases .

HY-134299

8-CPT-cAMP-AM 8-(4-Chlorophenylthio)-cAMP-AM	Ras PKA	Cardiovascular Disease Metabolic Disease Cancer
8-CPT-cAMP-AM (8-(4-Chlorophenylthio)-cAMP-AM) is an *Epac/PKA* activator. 8-CPT-cAMP-AM potentiates glucose-dependent first- and second-phase insulin secretion, induces β-cell depolarization, modulates intracellular calcium via influx and ryanodine-sensitive store mobilization, and facilitates calcium-induced calcium release resistant to PKA inhibition. 8-CPT-cAMP-AM can be used for the research of cardiac hypertrophy, diabetic cardiomyopathy, and melanoma .

HY-116312

8-pCPT-2′-O-Me-cAMP 8-CPT-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-138956

MAY0132	NF-κB RSV	Infection
MAY0132 is a potent and selective *EPAC2* inhibitor with an IC₅₀ of 0.4 μM. MAY0132 significantly inhibits replication of HMPV, AdV and RSV, reduces viral infection-induced cytokine/chemokine production, and inhibits NF-κB activation. MAY0132 has antiviral activity and can be used in the study of respiratory virus infection .

HY-117064

NY-0173	Ras	Others
NY-0173 is an antagonist of Exchange proteins directly activated by cAMP (EPAC), with IC₅₀s of 3.5 μM (EPAC2)and 4.0 μM (EPAC1) respectively. NY-0173 can be used to elucidate the biological functions of EPAC .

HY-134263

8-Br-cAMP-AM	PKA Ras	Cardiovascular Disease
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .

HY-134308

8-NBD-cAMP sodium	Fluorescent Dye	Others
8-NBD-cAMP sodium is a fluorescently labeled cyclic adenosine phosphate (cAMP) analogue. 8-NBD-cAMP sodium retains a similar biological activity to cAMP, regulating their activity by binding to specific proteins such as *EPACs* or PKA. 8-NBD-cAMP sodium can be used in fluorescent competitive binding experiments to evaluate the binding affinity of newly synthesized *EPAC1* agonists to *EPAC1* proteins .

HY-134340

8-pMeOPT-2'-O-Me-cAMP 8-(4-Methoxyphenylthio)-2'-O-Me-cAMP	Ras	Others
8-pMeOPT-2'-O-Me-cAMP is an analogue of the signal molecule cAMP and a potent stimulator of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP does .

HY-134332

8-pCPT-5'-AMP 8-(4-Chlorophenylthio)-5'-AMP	PKA PKG	Others
8-pCPT-5'-AMP is an analogue of 5'-AMP and a lipophilic activator of PKA, PKG and *Epac* (exchange protein activated by cAMP) .

HY-131766

2'-O-Me-cAMP 2'-O-Methyladenosine-3',5'-cyclic monophosphate	Ras	Others
2'-O-Me-cAMP is an analogue of natural signal molecule cAMP and a selective stimulator of the exchange factors activated by cAMP (Epac) with low membrane permeability .

HY-134264

8-Br-2'-O-Me-cAMP	Ras	Cardiovascular Disease Neurological Disease
8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research .

HY-131842

6-Bn-cAMP N6-Benzyladenosine-3',5'-cyclic monophosphate	PKA	Cancer
6-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinase (PKA) which does not activate Epac. 6-Bn-cAMP increases hydrolytic stability against PDE, esterases, amidases and considerably higher membrane permeability compared to cAMP .

HY-160864

Torbafylline HWA 448	Phosphodiesterase (PDE)	Cancer
Torbafylline is a PDE inhibitor. Torbafylline mitigates protein breakdown in rat skeletal muscle following burns by activating the PDE4/cAMP/EPAC/PI3K/Akt signaling pathway. Torbafylline suppresses the increased ubiquitin-proteasome-dependent protein degradation observed in the skeletal muscles of rats susceptible to cancer and sepsis .

HY-137635

Sp-6-Phe-cAMPS	PKA	Neurological Disease
Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases .

HY-RS11662

RAPGEF3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAPGEF3 Human Pre-designed siRNA Set A contains three designed siRNAs for RAPGEF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAPGEF3 Human Pre-designed siRNA Set A RAPGEF3 Human Pre-designed siRNA Set A

HY-RS11663

RAPGEF4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAPGEF4 Human Pre-designed siRNA Set A contains three designed siRNAs for RAPGEF4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAPGEF4 Human Pre-designed siRNA Set A RAPGEF4 Human Pre-designed siRNA Set A

HY-134348

8-pHPT-2'-O-Me-cAMP 8-(4-Hydroxyphenylthio)-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-pHPT-2'-O-Me-cAMP is a cAMP analog and an *Epac* agonist. 8-pHPT-2'-O-Me-cAMP can be used in cardiac research .

HY-137630

Sp-8-pCPT-2'-O-Me-cAMPS	Ras	Metabolic Disease
Sp-8-pCPT-2'-O-Me-cAMPS is an activator of *EPAC*. Sp-8-pCPT-2'-O-Me-cAMPS can be used in endocrine metabolism related research .

HY-137381

6-Bnz-cAMP N6-Benzoyl-cAMP	PKA Potassium Channel	Metabolic Disease
6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K ⁺ channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K ⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .

HY-137641

Sp-8-Br-2'-O-Me-cAMPS	Ras	Metabolic Disease
Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog. Sp-8-Br-2'-O-Me-cAMPS is an activator of *EPAC*. Sp-8-Br-2'-O-Me-cAMPS can be used in metabolism-related studies .

HY-107543R

8-pCPT-2′-O-Me-cAMP sodium (Standard) 8-CPT-2'-O-Me-cAMP sodium (Standard)	Reference Standards Ras	Cardiovascular Disease
8-pCPT-2′-O-Me-cAMP sodium (Standard) is the analytical standard of 8-pCPT-2′-O-Me-cAMP (sodium) (HY-107543). This product is intended for research and analytical applications. 8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP) sodium, an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀ >10 μM). 8-pCPT-2′-O-Me-cAMP sodium stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP sodium is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP sodium enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .

HY-108539R

CE3F4 (Standard)	Reference Standards Ras	Cardiovascular Disease
CE3F4 (Standard) is the analytical standard of CE3F4 (HY-108539). This product is intended for research and analytical applications. CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC₅₀s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.

HY-182273

DM243	STAT Acyltransferase	Others
DM243 is an *EPAC1* activator and STAT3 modulator with an pIC₅₀ of 4.769. DM243 increases GTP-bound Rap1 levels in *EPAC1*-expressing cells, with no activation of *EPAC2* or PKA. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts .

HY-123795

NY0123	Ras Akt ERK VEGFR	Cancer
NY0123 is a *EPAC1* inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer .

HY-182274

DM245	Acyltransferase STAT	Others
DM245 is an *EPAC1* activator and STAT3 phosphorylation inhibitor with a target pIC₅₀ of 4.801. DM245 activates *EPAC1* to increase Rap1-GTP levels, with no activation of *EPAC2* or PKA. DM245 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM245 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing αSMA and Collagen I levels. DM245 exhibits minimal cytotoxicity in normal human lung fibroblasts, with negligible loss of intact nuclei after 72 h exposure .

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (1) Mouse (2)
Application:	IHC-P (1) ICC/IF (1) IP (1) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80120

	Epac1 Antibody (YA459)	WB, IHC-P, IP, ICC/IF	Human, Mouse
	Epac1 Antibody (YA459) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Epac1.

HY-P82578

	Epac2 Antibody (YA2323) CAMP GEFII; CAMPGEFII; CGEF2; EPAC2; Rapgef4	WB	Human, Mouse, Rat
	Epac2 Antibody (YA2323) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Epac2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

RAPGEF3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
RAPGEF3 Human Pre-designed siRNA Set A contains three designed siRNAs for RAPGEF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAPGEF4 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
RAPGEF4 Human Pre-designed siRNA Set A contains three designed siRNAs for RAPGEF4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: